
scienceJun 28, 201823:29pending
How One Accelerator Tries to Give Early-Stage Drug Developers an Edge
About this episode
Incubators and accelerators come in many flavors. Mass Innovation Labs is seeking to distinguish itself with its approach to providing research scientists with infrastructure comparable to what a discovery and development team might have at a mature pharmaceutical company. We spoke to Amrit Chaudhuri, CEO of Mass Innovation Labs, about what it does to accelerate the movement of its client companies down the path to commercialization, what its track record has been, and how it differs from the competition.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report

Resetting Severe Allergies at Their Cellular Source
The Bio Report
Sep 2, 202633:17pending

Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Aug 26, 202629:35pending

Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
Aug 19, 202634:19pending

How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report
Aug 12, 202638:31pending